NCT05102409View on ClinicalTrials.gov

An Exploratory Crossover Clinical Trial to Compare the Activity of Reproxalap and Lifitegrast in a Dry Eye Disease Chamber

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

September 9, 2021

Primary Completion Date

October 25, 2021

Study Completion Date

October 25, 2021

Conditions
Dry Eye
Interventions
DRUG

Reproxalap Ophthalmic Solution (0.25%)

Reproxalap Ophthalmic Solution (0.25%) dosed once

DRUG

Xiidra® (5% lifitegrast ophthalmic solution)

Xiidra® (5% lifitegrast ophthalmic solution) dosed once

Trial Locations (1)

Unknown

Cliantha Research, Mississauga

Sponsors
All Listed Sponsors
lead

Aldeyra Therapeutics, Inc.

INDUSTRY